There is now extensive evidence that chelation of copper and/or iron can inhibit tumour growth in cell culture, animal models and human clinical trials. These effects are due to the essential role these metal ions play in a variety of biological processes, including DNA synthesis. As such, there is growing interest in the development of new agents that surpass the anti-tumor activity of traditional metal-binding drugs such as desferrioxamine (DFO). Since entering this field over 20 years ago, our laboratory has been particularly interested in novel aroylhydrazones, and more recently thiosemicarbazones, that bind iron and copper and inhibit tumor growth in vitro and in vivo. Our team have pioneered the development of a new class of agents, known as the di-2-pyridylketone thiosemicarbazones (DpT analogues) that show marked and selective anti-tumour activity.
|Number of pages||2|
|Publication status||Published - 2016|